Nextstellis is based on a novel drug called E4/DSRP. E4 refers not to ethanol content, but to estetrol which is a natural estrogen produced by the foetal liver during pregnancy. The DSRP refers to drospirenone (progestin).Nextstellis is claimed to have better efficacy and safety, such as bleeding control, relative to other estrogen-based alternatives.In April 2021, the US Food and Drug Administration approved Nextstellis and it was launched in June 2021 – the first estrogen-based prophylactic launched there in 50 years.In November 2021, Australia’s Therapeutic Goods Administration (TGA) followed suit, with a launch expected in mid-2022.The US contraceptives market is worth around $US4 billion and here it’s worth about $125 million a year.the company still aims for peak annual Nextstellis sales of $US200 million
MYX Price at posting:
$3.37 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)